| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
PDE2A PDE4
Ayanin targets interleukin (IL)-4 production from basophils. IL-4 is a key cytokine in allergic inflammation, promoting IgE production and Th2 cell differentiation. Ayanin inhibits IL-4 production with an IC50 of 2.2 μM. By inhibiting IL-4 production, Ayanin may reduce allergic inflammation. The compound also has vasorelaxant activity, suggesting additional mechanisms of action. As a flavonoid, Ayanin may also have antioxidant and anti-inflammatory properties. |
|---|---|
| ln Vitro |
Purified basophiles produce less interleukin (IL)-4 when ayanin is present, with an IC50 value of 2.2 μM[1].
Ayanin demonstrates in vitro inhibition of IL-4 production from purified basophils with an IC50 of 2.2 μM. The compound has vasorelaxant activity. Ayanin is a trimethoxyflavone functionally related to quercetin. These in vitro findings support the compound's potential for treating allergic asthma and other inflammatory conditions. Further in vitro studies are needed to fully characterize its activity profile and mechanisms of action. |
| ln Vivo |
In vivo activity data for Ayanin are not extensively documented. The compound may have potential for use in treating allergic asthma, suggesting possible in vivo efficacy in animal models of asthma. Its vasorelaxant activity suggests potential cardiovascular effects. Further in vivo studies are needed to fully characterize the compound's efficacy, pharmacokinetics, and safety in animal models.
|
| Enzyme Assay |
The in vitro assay for Ayanin involves measuring its inhibition of IL-4 production from purified basophils. Basophils are isolated from human blood and stimulated with appropriate stimuli to induce IL-4 production. Ayanin is added at various concentrations. IL-4 levels in the supernatant are measured by ELISA. The IC50 value is determined by fitting the inhibition data to a dose-response curve. The assay buffer and culture conditions are optimized for basophil viability and function.
|
| Cell Assay |
In vitro cellular assays for Ayanin typically use basophils or other immune cells to assess its effects on IL-4 production. Cells are treated with Ayanin at various concentrations and stimulated to induce IL-4 production. IL-4 levels are measured by ELISA. Cell viability is assessed using standard assays to ensure that the observed inhibition is not due to cytotoxicity. Additionally, the compound's effects on other cytokines can be assessed. These assays confirm the compound's cellular activity.
|
| Animal Protocol |
In vivo animal experiments for Ayanin would typically use animal models of allergic asthma or other allergic diseases. The compound would be administered via oral or parenteral routes. Airway inflammation, IgE levels, and IL-4 production in tissues would be assessed. Vasorelaxant effects could be evaluated in cardiovascular models. Further studies are needed to fully characterize the compound's in vivo efficacy and safety.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Ayanin are not extensively documented. As a flavonoid with a molecular weight of 344.32, the compound is expected to have moderate bioavailability. Its trimethoxyflavone structure may influence its absorption, distribution, metabolism, and excretion (ADME) properties. Further pharmacokinetic studies are necessary to fully characterize its PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Ayanin are not extensively available. As a natural flavonoid, the compound is generally considered to have a favorable safety profile. Standard cytotoxicity assays in cell lines may have been performed to assess safety margins. Further toxicological studies would be required for clinical development.
|
| References | |
| Additional Infomation |
3',5-Dihydroxy-3,4',7-Trimethoxyflavonoid is a trimethoxyflavonoid, a derivative of quercetin, in which the hydroxyl groups at the 3, 4', and 7 positions are replaced by methoxy groups. It is a plant metabolite. It is both a dihydroxyflavonoid and a trimethoxyflavonoid. It is functionally related to quercetin. It is the conjugate acid of 3',5-Dihydroxy-3,4',7-Trimethoxyflavonoid (1-). Flavonoid glycosides have been reported in Plumeria rubra, Melicope semecarpifolia, and other organisms with relevant data.
Ayanin (quercetin-3,7,4'-O-trimethylether) inhibits IL-4 production from basophils with an IC50 of 2.2 μM. It has vasorelaxant activity and may have potential for treating allergic asthma. Ayanin is a trimethoxyflavone functionally related to quercetin. It has a molecular weight of 344.32 and formula C18H16O7. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C18H16O7
|
|---|---|
| Molecular Weight |
344.32
|
| Exact Mass |
344.089
|
| CAS # |
572-32-7
|
| PubChem CID |
5280682
|
| Appearance |
White to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
600.8±55.0 °C at 760 mmHg
|
| Melting Point |
173℃
|
| Flash Point |
221.5±25.0 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.654
|
| LogP |
2.43
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
532
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)OC)O)OC)O
|
| InChi Key |
KPCRYSMUMBNTCK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O7/c1-22-10-7-12(20)15-14(8-10)25-17(18(24-3)16(15)21)9-4-5-13(23-2)11(19)6-9/h4-8,19-20H,1-3H3
|
| Chemical Name |
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,7-dimethoxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (726.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL | |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL | |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
